INT287380

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.18
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 12
Total Number 14
Disease Relevance 11.97
Pain Relevance 0.34

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytoplasm (VEGFA, Kdr) extracellular space (VEGFA) growth (VEGFA)
extracellular region (VEGFA) proteinaceous extracellular matrix (VEGFA) plasma membrane (Kdr)
Anatomy Link Frequency
vasculature 1
endothelial cell 1
VEGFA (Homo sapiens)
Kdr (Mus musculus)
Pain Link Frequency Relevance Heat
antagonist 7 94.68 High High
imagery 126 92.08 High High
cytokine 27 80.16 Quite High
Inflammation 34 79.28 Quite High
Kinase C 5 70.16 Quite High
cINOD 2 40.92 Quite Low
positron emission tomography 35 5.00 Very Low Very Low Very Low
cva 29 5.00 Very Low Very Low Very Low
palliative 14 5.00 Very Low Very Low Very Low
anesthesia 10 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Pancreatic Cancer 15 99.46 Very High Very High Very High
Cancer 825 99.28 Very High Very High Very High
Death 12 99.16 Very High Very High Very High
Acute Liver Failure 66 98.76 Very High Very High Very High
Non-small-cell Lung Cancer 404 94.56 High High
Breast Cancer 17 90.04 High High
Glioma 5 89.28 High High
Hemangiosarcoma 5 88.96 High High
Corneal Neovascularization 74 88.84 High High
Stomach Cancer 3 88.24 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
VEGF exerts its activity by binding to several high-affinity transmembrane endothelial cell receptors, especially VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1).
VEGF Binding (binding) of VEGFR in endothelial cell
1) Confidence 0.18 Published 2009 Journal Molecular Vision Section Body Doc Link PMC2779062 Disease Relevance 0.34 Pain Relevance 0.04
It prevents VEGF-A from ligating to its endothelial receptors, VEGFR-1 and VEGFR-2 [22,23], but does not neutralize other members of the VEGF gene family, such as VEGF-B or VEGF-C [24-26].
VEGF Binding (ligating) of VEGFR
2) Confidence 0.18 Published 2009 Journal Molecular Vision Section Body Doc Link PMC2779062 Disease Relevance 0.45 Pain Relevance 0
Recently, our group evaluated vascular response to antiangiogenic and chemotherapy in mouse models of pancreatic cancer using MB targeted against VEGFR2, the VEGF:VEGFR complex, and endoglin [20].
VEGF Binding (complex) of VEGFR associated with pancreatic cancer
3) Confidence 0.15 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2902148 Disease Relevance 1.29 Pain Relevance 0.05
The Nrps can also bind to certain heparin binding isofoms of VEGF (e.g., VEGF165) to enhance the binding of VEGF to VEGFR1, and VEGFR2 (Figure 1) [31, 32].
VEGF Binding (binding) of VEGFR2
4) Confidence 0.12 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2902148 Disease Relevance 0.67 Pain Relevance 0.08
We found that targeting to VEGFR2, endoglin, or the VEGF:VEGFR complex was specific for tumor vasculature as there was no signal enhancement in nontumor tumor tissue.
VEGF Binding (complex) of VEGFR in vasculature associated with cancer
5) Confidence 0.11 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2902148 Disease Relevance 1.16 Pain Relevance 0.04
Recently, our group evaluated vascular response to antiangiogenic and chemotherapy in mouse models of pancreatic cancer using MB targeted against VEGFR2, the VEGF:VEGFR complex, and endoglin [20].
VEGF Binding (complex) of VEGFR associated with pancreatic cancer
6) Confidence 0.11 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2902148 Disease Relevance 1.29 Pain Relevance 0.05
Recently, our group evaluated vascular response to antiangiogenic and chemotherapy in mouse models of pancreatic cancer using MB targeted against VEGFR2, the VEGF:VEGFR complex, and endoglin [20].
VEGF Binding (complex) of VEGFR2 associated with pancreatic cancer
7) Confidence 0.11 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2902148 Disease Relevance 1.29 Pain Relevance 0.05
inhibiting VEGF itself using neutralizing anti-VEGF monoclonal antibodies or soluble receptorsVEGF receptor (VEGFR) blockade using anti-VEGFR monoclonal antibodiesinhibiting VEGFR signalling with small molecule VEGFR tyrosine kinase inhibitors.


VEGF Binding (signalling) of VEGFR
8) Confidence 0.03 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012552 Disease Relevance 1.00 Pain Relevance 0
inhibiting VEGF itself using neutralizing anti-VEGF monoclonal antibodies or soluble receptorsVEGF receptor (VEGFR) blockade using anti-VEGFR monoclonal antibodiesinhibiting VEGFR signalling with small molecule VEGFR tyrosine kinase inhibitors.


VEGF Binding (signalling) of VEGFR
9) Confidence 0.03 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012552 Disease Relevance 0.94 Pain Relevance 0
inhibiting VEGF itself using neutralizing anti-VEGF monoclonal antibodies or soluble receptorsVEGF receptor (VEGFR) blockade using anti-VEGFR monoclonal antibodiesinhibiting VEGFR signalling with small molecule VEGFR tyrosine kinase inhibitors.


VEGF Binding (signalling) of anti-VEGFR
10) Confidence 0.03 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012552 Disease Relevance 0.94 Pain Relevance 0
On a related note, sVEGFR-3 can not only bind VEGFR-3 but also acts as a trap for VEGF-C, which blocks VEGFR-3 signaling [2,5].
VEGF Binding (trap) of sVEGFR-3
11) Confidence 0.01 Published 2010 Journal BMC Med Section Body Doc Link PMC2989928 Disease Relevance 1.13 Pain Relevance 0.05
These results indicated that VEGF-VEGFR interaction was a major regulator in the maintenance of the SEC architecture in Gal-N+LPS-induced AHF.
VEGF Binding (interaction) of VEGFR associated with acute liver failure
12) Confidence 0.01 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2933582 Disease Relevance 0.48 Pain Relevance 0
These results indicated that VEGF-VEGFR interaction was a major regulator in the maintenance of the SEC architecture in Gal-N+LPS-induced AHF.
VEGF Binding (interaction) of VEGFR associated with acute liver failure
13) Confidence 0.01 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2933582 Disease Relevance 0.48 Pain Relevance 0
These co-ordinate effects by VEGF and VEGFR interaction should contribute to decrease the overall survival of the R2-mAb-treated group with AHF in the current study.
VEGF Binding (interaction) of VEGFR associated with acute liver failure
14) Confidence 0.01 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2933582 Disease Relevance 0.50 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox